Mentions
Extended reach
Total likes
Video views
AI synopsis
Discussions reflect a high level of interest and engagement through comments that praise the study’s findings, such as 'promising results' and 'one-of-a-kind' vaccine, and cite specific immune responses like mucosal immunity. The tone indicates support and curiosity, but some posts also note the need for further clinical trials to confirm impact.
Most discussions acknowledge the positive findings of the vaccine study, emphasizing immune response and reduced viral shedding, which indicates general support.
The discussions display high interest, with multiple posts highlighting the promising phase 2 results and potential applications, using words like 'promising' and 'innovative'.
The posts exhibit deep engagement by referencing specific results, such as mucosal immunity and immune markers, and mentioning related research or companies, indicating active interest and analysis.
Though the conversations recognize the significance of the findings for vaccine development, many are still exploratory and anticipate future results; thus, the impact is seen as potentially high but not definitively transformative yet.
An oral norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challenge study | Science Translational Medicine www.science.org/doi/10.1126/...
より多様なウイルス型に対応する二価経口ワクチンも開発中。 今回の試験で血清や糞便中抗体が感染防御を予測する指標に使えそうという知見も得られ、今後は臨床試験もより発展してゆくかもしれない。 論文リンク https://t.co/mCAt2OzH3n
tabletki, a konieczne będą też badania kliniczne 3 fazy. End. Źródła: 1.https://t.co/rjx8CpdOOr 2.https://t.co/Mc04RTKBSN 3.https://t.co/w3M9ray8dF
An oral tablet vaccine for #norovirus generates strong immune responses in the mucosa against the viral VP1 protein and reduces shedding of the virus in vaccinated volunteers, according to results from a new phase 2 trial. https://t.co/05vLzo8pLY @Vaxart https://t.co/oFfcgJpGWh
An oral norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challenge study https://t.co/EVE4Iegan3 @ScienceTM https://t.co/KYj9zIJrY6
An oral tablet vaccine for #norovirus generates strong immune responses in the mucosa against the viral VP1 protein and reduces shedding of the virus in vaccinated volunteers, according to results from a new phase 2 trial. https://t.co/05vLzo8pLY @Vaxart https://t.co/QHfb0d1e8q
Vaxart has released Phase 2b challenge study results demonstrating a 30 reduction in norovirus infection, strong mucosal immunity, and reduced viral shedding, indicating potential for community spread reduction and…
Vaxart has announced positive Phase 2b results for its oral norovirus vaccine, demonstrating safety, immunogenicity, and a 30% reduction in infection. The study highlights mucosal immunity and identifies immune…
RT @AgnieszkaSzust3: tabletki, a konieczne będą też badania kliniczne 3 fazy. End. Źródła: 1.https://t.co/rjx8CpdOOr 2.https://t.co/Mc04RT…
RT @AgnieszkaSzust3: tabletki, a konieczne będą też badania kliniczne 3 fazy. End. Źródła: 1.https://t.co/rjx8CpdOOr 2.https://t.co/Mc04RT…
tabletki, a konieczne będą też badania kliniczne 3 fazy. End. Źródła: 1.https://t.co/rjx8CpdOOr 2.https://t.co/Mc04RTKBSN 3.https://t.co/w3M9ray8dF
Phase2の論文はこちら（購読が必要です）https://t.co/x64xf5vtSQ
RT @carpe_diem0820: An oral norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challen…
RT @SnihIniciativa: 1/2 Američtí vědci testovali experimentální ústní vakcínu VXA-G1.1-NN, podávanou ve formě tablety, která má ochránit pr…
1/2 Američtí vědci testovali experimentální ústní vakcínu VXA-G1.1-NN, podávanou ve formě tablety, která má ochránit právě proti nejběžnějšímu typu noroviru. https://t.co/lV8gsD2Gc1
RT @carpe_diem0820: An oral norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challen…
RT @carpe_diem0820: An oral norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challen…
An oral norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challenge study 経口ノロウイルスワクチン、第2b相試験で粘膜免疫を誘導しウイルス排出を抑制 https://t.co/j2g9IiuMWk
RT @ScienceTM: An oral tablet vaccine for #norovirus generates strong immune responses in the mucosa against the viral VP1 protein and redu…
RT @ScienceTM: An oral tablet vaccine for #norovirus generates strong immune responses in the mucosa against the viral VP1 protein and redu…
An oral tablet vaccine for #norovirus generates strong immune responses in the mucosa against the viral VP1 protein and reduces shedding of the virus in vaccinated volunteers, according to results from a new phase 2 trial. https://t.co/05vLzo8pLY @Vaxart https://t.co/oFfcgJpGWh
RT @MDPHD_mouchoi: より多様なウイルス型に対応する二価経口ワクチンも開発中。 今回の試験で血清や糞便中抗体が感染防御を予測する指標に使えそうという知見も得られ、今後は臨床試験もより発展してゆくかもしれない。 論文リンク https://t.co/mCAt2O…
RT @MDPHD_mouchoi: より多様なウイルス型に対応する二価経口ワクチンも開発中。 今回の試験で血清や糞便中抗体が感染防御を予測する指標に使えそうという知見も得られ、今後は臨床試験もより発展してゆくかもしれない。 論文リンク https://t.co/mCAt2O…
RT @MDPHD_mouchoi: より多様なウイルス型に対応する二価経口ワクチンも開発中。 今回の試験で血清や糞便中抗体が感染防御を予測する指標に使えそうという知見も得られ、今後は臨床試験もより発展してゆくかもしれない。 論文リンク https://t.co/mCAt2O…
RT @MDPHD_mouchoi: より多様なウイルス型に対応する二価経口ワクチンも開発中。 今回の試験で血清や糞便中抗体が感染防御を予測する指標に使えそうという知見も得られ、今後は臨床試験もより発展してゆくかもしれない。 論文リンク https://t.co/mCAt2O…
より多様なウイルス型に対応する二価経口ワクチンも開発中。 今回の試験で血清や糞便中抗体が感染防御を予測する指標に使えそうという知見も得られ、今後は臨床試験もより発展してゆくかもしれない。 論文リンク https://t.co/mCAt2OzH3n
RT @ScienceTM: An oral tablet vaccine for #norovirus generates strong immune responses in the mucosa against the viral VP1 protein and redu…
RT @ScienceTM: An oral tablet vaccine for #norovirus generates strong immune responses in the mucosa against the viral VP1 protein and redu…
RT @ScienceTM: An oral tablet vaccine for #norovirus generates strong immune responses in the mucosa against the viral VP1 protein and redu…
An oral tablet vaccine for #norovirus generates strong immune responses in the mucosa against the viral VP1 protein and reduces shedding of the virus in vaccinated volunteers, according to results from a new phase 2 trial. https://t.co/05vLzo8pLY @Vaxart https://t.co/QHfb0d1e8q
$VXRT The paper + supplementary docs can be found here https://t.co/7iX0Fke8sh Just going through them now...
RT @LabWaggoner: An oral norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challenge…
Vaxart ($VXRT) just published Phase 2 data for their oral norovirus tablet vaccine (VXA-G1.1-NN) in Science Translational Medicine. Quick take.
RT @Benonewayin: @ScienceTM $VXRT @CruiseNorwegian @PrincessCruises #Vaxart #Norovirus #Data #Mucosal #Oral #Pill @FoxNews @CarnivalCruis…
@ScienceTM $VXRT @CruiseNorwegian @PrincessCruises #Vaxart #Norovirus #Data #Mucosal #Oral #Pill @FoxNews @CarnivalCruise One of a kind… Vaxart Norovirus data shows promising results. https://t.co/cgsXEZ9Ayu
https://t.co/GarddefL22
RT @LabWaggoner: An oral norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challenge…
$vxrt https://t.co/v4deRd4ZWE
RT @LabWaggoner: An oral norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challenge…
RT @LabWaggoner: An oral norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challenge…
Science Translational Medicine: An oral norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challenge study Becca A. Flitter et al www.science.org/doi/10.1126/...
An oral norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challenge study https://t.co/EVE4Iegan3 @ScienceTM https://t.co/KYj9zIJrY6
An oral norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challenge study www.science.org/doi/10.1126/...
RT @greg_folkers: Science Translational Medicine: An oral #norovirus vaccine generates mucosal immunity and reduces viral shedding in a pha…
Science Translational Medicine: An oral #norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challenge study Becca A. Flitter et al https://t.co/2Hb21IJY4O
An oral norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challenge study | Science Translational Medicine www.science.org/doi/10.1126/...